Lonza and arGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, have entered into a new, multi-product commercial license agreement for the production of arGEN-X's therapeutic antibodies. The license secures long-term access for arGEN-X and its strategic partners to Lonza's proprietary GS Xceed System for creation and development of cell lines to be utilized in the manufacture of biopharmaceuticals.

The GS Xceed license agreement builds upon the relationship between Lonza and arGEN-X. Lonza has manufactured two of arGEN-X's clinical-stage proprietary therapeutic antibodies to date, as well as a third program due to commence clinical trials in 2015. Under the new agreement, arGEN-X has access to the GS Xceed System for the development and manufacture of both current and future therapeutic antibody products.

The GS Xceed System is Lonza's latest innovation in mammalian protein expression, offering reduced cell line construction timelines and increased product yields. For products in the early stages of development, the system was designed to help create commercially viable production cell lines for integration into the Lonza platform process.

Source: Lonza